PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 215 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,884,245 | +5.5% | 704,700 | +68.0% | 0.01% | +16.7% |
| Q2 2023 | $5,577,448 | +20.3% | 419,357 | +4.7% | 0.01% | 0.0% |
| Q1 2023 | $4,636,308 | +54.6% | 400,372 | +9.2% | 0.01% | +50.0% |
| Q4 2022 | $2,998,608 | +82.6% | 366,578 | +25.0% | 0.00% | +100.0% |
| Q3 2022 | $1,642,000 | +96.4% | 293,210 | +55.1% | 0.00% | +100.0% |
| Q2 2022 | $836,000 | -65.8% | 189,058 | -29.6% | 0.00% | -50.0% |
| Q1 2022 | $2,445,000 | -49.7% | 268,658 | +13.2% | 0.00% | -50.0% |
| Q4 2021 | $4,858,000 | -18.3% | 237,435 | +2.0% | 0.00% | -33.3% |
| Q3 2021 | $5,947,000 | -19.1% | 232,769 | +1.8% | 0.01% | -14.3% |
| Q2 2021 | $7,348,000 | -1.9% | 228,552 | +1.6% | 0.01% | -12.5% |
| Q1 2021 | $7,493,000 | +48.3% | 224,954 | +15.5% | 0.01% | +33.3% |
| Q4 2020 | $5,051,000 | +335.1% | 194,727 | +65.5% | 0.01% | +200.0% |
| Q3 2020 | $1,161,000 | – | 117,671 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |